Pipeline » Markets
Meditor introduces a new ethical platform for the treatment of hypotension and hypotension related disorders. Ethical drugs such as MTR-105, MTR-106 and MTR-107 are expected to significantly expand the addressable market for hypotension-related disorders since they offer clear advantages over existing treatments. Presently there is no satisfactory treatment for most hypotension-related disorders. Current sympathomimetic drugs yield serious side effects and suffer from several limitations and drawbacks. Therefore, the acute hypotension-related disorder area offers an extraordinary opportunity for Meditor to address an unmet medical need.
Acute hypotension is a common critical emergency condition, occurring in cases such as trauma, major surgery and septic shock. As blood pressure drops dramatically, organ systems shut down leading to decrease in cardiac and cerebral perfusion and to kidney failure. Management of hypotension in such medical emergencies has proven to be a critical factor in the patient’s chances for survival.
Hemodialysis is the most common procedure for removing metabolic waste products, excess fluid, and toxic substances from the bloodstream in patients with compromised renal function. This procedure is essential for the survival of end-stage renal disease (ESRD) patients whose kidneys are not capable of processing waste. Intradialytic hypotension is considered the most significant complication of routine hemodialysis in end-stage renal disease patients occurring in 10% to 30% of all dialysis treatments.
According to the National Institutes of Health, the approximate number of ESRD patients in the United States requiring dialysis treatments has grown from 66,000 at the end of 1982 to 300,000 at the end of 2001, representing an annual growth rate of approximately 9%. The United States Renal Data System (USRDS) is predicting that the number of individuals on dialysis in the US will hit 520,000 by the year 2010, doubling the number of patients receiving treatment at the end of 2005. Most of this growth is attributable to factors having a high correlation with kidney disease including an aging population and increasing obesity and diabetic diseases. Every year about 1,400,000 patients worldwide undergo hemodialysis treatment sessions and this number is expected to grow at an approximate rate of 8% annually.
Migraine has been defined by the World Health Organization as one of the top five disabling diseases in the world and it is estimated that approximately 10% of the US population experience migraine attacks.
More than 31 million Americans suffer from migraine. The mean prevalence of migraine is reported to be 17% for women and 6% for men. Half of these patients may need treatment; this is equivalent to 15,500,000 people in the United States alone.
The migraine market was estimated at $3 billion in 2001; it reached $3.5 billion in 2004 and is poised for further substantial growth given the large untapped population of patients and increased patient awareness. The expected annual growth rate is 10% and it is projected to reach $7.4 billion by 2012.
